ONCT Stock Overview A clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Oncternal Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Oncternal Therapeutics Historical stock prices Current Share Price US$0.53 52 Week High US$13.14 52 Week Low US$0.53 Beta 1.2 1 Month Change -64.42% 3 Month Change -86.90% 1 Year Change -93.09% 3 Year Change -99.12% 5 Year Change -99.43% Change since IPO -99.63%
Recent News & Updates
Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from NASDAQ Composite Index Dec 04 Nasdaq Provides Notice on Oncternal's Common Stock Suspension on December 3, 2024 Nov 25
New minor risk - Share price stability Aug 12
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 11
Oncternal Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
Oncternal Therapeutics, Inc. Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer Jul 15 See more updates
Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from NASDAQ Composite Index Dec 04 Nasdaq Provides Notice on Oncternal's Common Stock Suspension on December 3, 2024 Nov 25
New minor risk - Share price stability Aug 12
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 11
Oncternal Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
Oncternal Therapeutics, Inc. Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer Jul 15
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation Jun 14
Price target decreased by 9.8% to US$27.67 Jun 02
Consensus estimates of losses per share improve by 10% May 31
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer May 31
Consensus EPS estimates fall by 12% May 12
Oncternal Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Oncternal Therapeutics, Inc., Annual General Meeting, Jun 20, 2024 Apr 28
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer Apr 19
Consensus revenue estimates fall by 25% Apr 16
Non-Independent Director recently bought US$59k worth of stock Apr 02
Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat Mar 10
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth? Mar 03
Oncternal Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024 Mar 01
Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science Feb 01
Price target decreased by 8.5% to US$39.67 Jan 29
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer Jan 09
Oncternal Therapeutics Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq’s Minimum Bid Price Requirement Jan 05
Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Dec 26
Consensus revenue estimates increase by 13% Dec 05
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 11
Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation Nov 06
Oncternal Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer Oct 27
Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board Oct 26
New major risk - Financial position Oct 15
Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement Oct 08
Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement Oct 07
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer Oct 06
Consensus revenue estimates increase by 26%, EPS downgraded Aug 17
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 13
Oncternal Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely Jul 12
Oncternal Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Study of ROR1 Targeting Autologous CAR T, ONCT-808, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Jun 07
Oncternal Therapeutics, Inc., Annual General Meeting, Jun 28, 2023 May 17
Consensus revenue estimates increase by 11% May 11
First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat May 06
Consensus revenue estimates decrease by 26%, EPS upgraded Apr 05
Consensus revenue estimates increase by 11% Mar 23
Consensus revenue estimates fall by 30% Mar 16
Full year 2022 earnings: EPS in line with expectations, revenues disappoint Mar 11
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate Jan 12
Oncternal Therapeutics, Inc. Appoints Jill DeSimone to the Board of Directors Jan 05
Oncternal Therapeutics, Inc. Announces the Resignation of Jinzhu Chen from the Board of Directors Dec 26
Oncternal Therapeutics, Inc. Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib Dec 13
Price target decreased to US$9.42 Nov 16
Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.20 loss in 3Q 2021) Nov 04
Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022 Nov 04
Oncternal Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma Oct 06
FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy Oct 03
Oncternal Therapeutics, Inc Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL Sep 28
Oncternal Therapeutics begins phase 3 study of zilovertamab Sep 27
Oncternal Therapeutics: Selling For Under Cash Value Sep 02
Oncternal Therapeutics, Inc. Submitted an Investigational New Drug Application (“IND”) for ONCT-808 Sep 01
Consensus forecasts updated Aug 16
Price target decreased to US$9.42 Aug 12
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 11
Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M Aug 09
Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation Aug 07
Oncternal Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Aug 03
High number of new directors Jul 31
Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in Combination with Ibrutinib for Patients with MCL Jul 15
Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study Jul 14 Oncternal Therapeutics, Inc. Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress
Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve Jun 07
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib At Asco 2022 May 28
Consensus revenue estimates increase by 24% May 12
Price target decreased to US$10.80 May 09
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 06
Oncternal Therapeutics, Inc., Annual General Meeting, Jun 16, 2022 May 02
Price target decreased to US$12.20 Apr 27
High number of new and inexperienced directors Apr 27
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate Apr 12
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 12
Price target decreased to US$13.40 Feb 26
Oncternal Therapeutics, Inc. Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma Jan 06
Oncternal Therapeutics: Trading Near Cash With Impressive Results Jan 04
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib At ASH 2021 Dec 15
Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans Nov 09
Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.22 loss in 3Q 2020) Nov 06
Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company Oct 10
Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.34 loss in 2Q 2020) Aug 08
Oncternal: Solid Data In 2 Cancers With High Unmet Need Jun 17
Independent Director Man Cho has left the company Jun 05 Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib At ASCO 2021
First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.31 loss in 1Q 2020) May 09
We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth May 05
New 90-day high: US$8.62 Mar 16 Shareholder Returns ONCT US Biotechs US Market 7D -29.5% -2.3% -2.6% 1Y -93.1% -6.3% 24.5%
See full shareholder returns
Return vs Industry: ONCT underperformed the US Biotechs industry which returned 15% over the past year.
Return vs Market: ONCT underperformed the US Market which returned 32.2% over the past year.
Price Volatility Is ONCT's price volatile compared to industry and market? ONCT volatility ONCT Average Weekly Movement 28.7% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.7% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ONCT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ONCT's weekly volatility has increased from 19% to 29% over the past year.
About the Company Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Show more Oncternal Therapeutics, Inc. Fundamentals Summary How do Oncternal Therapeutics's earnings and revenue compare to its market cap? ONCT fundamental statistics Market cap US$1.56m Earnings (TTM ) -US$34.57m Revenue (TTM ) US$2.16m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ONCT income statement (TTM ) Revenue US$2.16m Cost of Revenue US$25.09m Gross Profit -US$22.93m Other Expenses US$11.65m Earnings -US$34.57m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -11.68 Gross Margin -1,060.99% Net Profit Margin -1,599.95% Debt/Equity Ratio 0%
How did ONCT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/04 09:14 End of Day Share Price 2024/12/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Oncternal Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kaveri Pohlman BTIG Li Wang Watsek Cantor Fitzgerald & Co. Carl Byrnes Northland Capital Markets
Show 1 more analysts 
